Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors
作者:Mark Zak、Po-wai Yuen、Xiongcai Liu、Snahel Patel、Deepak Sampath、Jason Oeh、Bianca M. Liederer、Weiru Wang、Thomas O’Brien、Yang Xiao、Nicholas Skelton、Rongbao Hua、Jasleen Sodhi、Yunli Wang、Lei Zhang、Guiling Zhao、Xiaozhang Zheng、Yen-Ching Ho、Kenneth W. Bair、Peter S. Dragovich
DOI:10.1021/acs.jmedchem.6b00697
日期:2016.9.22
NAMPT inhibitors may show potential as therapeutics for oncology. Throughout our NAMPT inhibitor program, we found that exposed pyridines or related heterocyclic systems in the left-hand portion of the inhibitors are necessary pharmacophores for potent cellular NAMPT inhibition. However, when combined with a benzyl group in the center of the inhibitors, such pyridine-like moieties also led to consistent
NAMPT抑制剂可能显示出作为肿瘤治疗剂的潜力。在整个NAMPT抑制剂计划中,我们发现在抑制剂左手侧暴露的吡啶或相关杂环系统是有效抑制细胞NAMPT的必要药效团。但是,当在抑制剂中心与苄基结合时,此类吡啶样部分也导致对CYP2C9的持续且有效的抑制。为了减少CYP2C9的抑制作用,使用了一种平行合成方法来鉴定Fsp3含量增加的中央苄基取代基。因此,发现了一个螺环的中心基序,该基序与左手的吡啶(或吡啶样系统)结合,可提供对细胞有效的NAMPT抑制剂,并具有最小的CYP2C9抑制作用。68,一种高效的NAMPT抑制剂,在小鼠肿瘤异种移植模型中具有出色的功效,并且在所测试的浓度下缺乏可测量的CYP2C9抑制作用。